Great news! EMA approval for Ph3 in Europe & conditions for accelerated approval (interim data). Another box ticked. Now we await the FDA.
It’s interesting because there were a few naysayers stating FSGS wouldn’t move to a Ph3 on the data from a small Ph2 in rare disease (FSGS).
Have a bit more of a look on the weekend.
GLTAH
- Forums
- ASX - By Stock
- DXB
- Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA, page-7
-
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
49.0¢ |
Change
0.040(8.89%) |
Mkt cap ! $269.6M |
Open | High | Low | Value | Volume |
46.0¢ | 50.5¢ | 46.0¢ | $2.255M | 4.621M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 49.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
49.5¢ | 21052 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.490 |
1 | 38000 | 0.485 |
2 | 19350 | 0.480 |
2 | 114893 | 0.470 |
2 | 14280 | 0.465 |
Price($) | Vol. | No. |
---|---|---|
0.495 | 21052 | 1 |
0.500 | 106103 | 3 |
0.505 | 100000 | 1 |
0.510 | 129000 | 3 |
0.515 | 160650 | 4 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |